Eric Leung

“The TCP program helps manufacturers save time and money when applying in Taiwan.”

Eric Leung
General Manager
Asia Actual Taiwan

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Sign Up For Our Newsletter to Stay Informed

Sign Up

Taiwan’s New TCP III in Effect as of January 1, 2022

Published on: September 2nd, 2022

Originally announced in May of 2021, the Taiwan FDA implemented the third generation of the Taiwan-Europe Technical Cooperation Program (TCP III) on January 1, 2022. The TCP program was established to help expedite the Quality System Documentation (QSD) portion of the TFDA’s review by accepting ISO 13485 audit reports from designated European Notified Bodies. The following Notified Bodies are participants of the TCP program and the official announcement can be found here.

  1. TÜV SÜD Product Service GmbH Zertifizierstellen
  2. TÜV Rheinland LGA Products GmbH
  3. MDC Medical Device Certification GmbH
  4. MEDCERT Zertifizierungs- Und Prüfungsgesellschaft Für Die Medizin GmbH
  5. GMED
  6. DEKRA Certification B.V.

Manufacturers prioritizing the Taiwanese market after receiving CE Marking should consider using one of the approved Notified Bodies to help expedite their market access.

Registration Overview in Taiwan

In Taiwan, medical device registration is overseen by the Taiwan Food and Drug Administration (Taiwan FDA), a division of the Ministry of Health and Welfare. Class I devices will go through an Administrative Review, and Class II, III, and New devices (no predicates) will go through both an Administrative and Technical Review, as well as a Quality System Document (QSD) Review. While fees have increased in Taiwan, the review fees are still relatively affordable compared to other markets in the region.

Once issued, licenses are valid for 5 years. Licenses in Taiwan are transferrable and will need to be completed by both the transferor and the transferee jointly. To learn more about the regulatory process in Taiwan, please click here.

Expedited Market Access For US/EU Approved Devices

Clinical data is only required for Class III IVDs and New products. Class II medical devices with approval in the US or EU can usually use existing documentation in place of the preclinical test, quality control procedure and test reports.

Grow with Us

Asia Actual is available to help navigate the medical device registration requirements and regulatory pathway for medical device and IVDs in Taiwan.

Contact Asia Actual for more information discussing the potential for your medical device or IVD in the Taiwanese market.

Blog Posts

Australia SaMD Transition Deadline

Australia’s SaMD Regulatory Deadline

Beginning on November 1st, 2024, Australia's Therapeutic Goods Administration will implement new rules surrounding software as a medical device (SaMD). While some SaMD will require additional regulatory requirements, other SaMD will be exempted from some, or excluded completely, from the new regulations.
Read more
Thai FDA Documentation Exemptions for Concise and Full Regulatory Pathways

Thai FDA Regulatory Documentation Exemptions

March 12, 2024: the Thai FDA released draft guidance updating the list of required documentation for Full and Concise Evaluation. For manufacturers registering a medical device in Thailand, certain documents are no longer required.
Read more
Hong Kong MDD adds Singapore HSA to Reference Country List

Hong Kong MDD Adds Singapore as Reference Country

Starting April 2nd, 2024, the Hong Kong Medical Device Division (MDD) accepts, on a regular basis, the marketing approvals obtained from the the Health Sciences Authority (HSA) of Singapore as a support of compliance of medical device to the "Essential Principles of Safety and Performance of Medical Devices" (Technical Reference: TR-004) under MDACS.
Read more